Bipolar disorder, schizophrenia, autism and intellectual disability are complex neurodevelopmental disorders, debilitating millions of people. Therapeutic progress is limited by poor understanding of underlying molecular pathways. Using a targeted search, we identified an enrichment of de novo mutations in the gene encoding the 330-kDa triple functional domain (TRIO) protein associated with neurodevelopmental disorders. By generating multiple TRIO antibodies, we show that the smaller TRIO9 isoform is the major brain protein product, and its levels decrease after birth. TRIO9 contains two guanine nucleotide exchange factor (GEF) domains with distinct specificities: GEF1 activates both Rac1 and RhoG; GEF2 activates RhoA. To understand the impact of disease-associated de novo mutations and other rare sequence variants on TRIO function, we utilized two FRET-based biosensors: a Rac1 biosensor to study mutations in TRIO (T)GEF1, and a RhoA biosensor to study mutations in TGEF2. We discovered that one autism-associated de novo mutation in TGEF1 (K1431M), at the TGEF1/Rac1 interface, markedly decreased its overall activity toward Rac1. A schizophrenia-associated rare sequence variant in TGEF1 (F1538Intron) was substantially less active, normalized to protein level and expressed poorly. Overall, mutations in TGEF1 decreased GEF1 activity toward Rac1. One bipolar disorder-associated rare variant (M2145T) in TGEF2 impaired inhibition by the TGEF2 pleckstrin-homology domain, resulting in dramatically increased TGEF2 activity. Overall, genetic damage to both TGEF domains altered TRIO catalytic activity, decreasing TGEF1 activity and increasing TGEF2 activity. Importantly, both GEF changes are expected to decrease neurite outgrowth, perhaps consistent with their association with neurodevelopmental disorders.
Introduction
Bipolar disorder, schizophrenia, autism and intellectual disability are complex neurodevelopmental disorders that debilitate $2.6% (1), 1.1% (2), 1.5% (3) and 1.0% (4) of individuals in the USA, respectively, and millions more worldwide. Current therapies do not fully ameliorate neurological disease symptoms. In particular, while pharmacologic therapies for schizophrenia and bipolar disorder can improve positive symptoms, they often fail to improve negative or cognitive symptoms, including deficits in social interactions, affective experience and clarity of thought (5, 6) . Similarly, predominant therapies for autism and intellectual disability do not address underlying cognitive abnormalities, but rather include specialized behavioral interventions and pharmacologic treatments for comorbid conditions, such as depression or anxiety (7) . There is a critical need for new therapeutic interventions, but progress is limited by a poor understanding of the molecular and cellular pathways underlying neurodevelopmental disorders.
For each of these disorders, genetic and environmental risk factors are believed to disrupt normal cognition and alter neuronal connectivity, as exemplified by alterations in dendrite and dendritic spine structure (8) (9) (10) (11) . For example, dendritic spines, the main receptive contacts for glutamatergic synapses, are significantly reduced in the prefrontal cortices of individuals with bipolar disorder (8) and schizophrenia (9) , and increased across multiple cortices in individuals with autism spectrum disorders (10) . Furthermore, a high degree of genetic overlap has been noted among these disorders, especially in genes related to synaptic stability and function (12) (13) (14) (15) (16) (17) , suggesting disruptions of common molecular mechanisms (18) . An abundance of neurologic disease-associated de novo mutations and rare sequence variants have been identified in the triple functional domain (TRIO) gene (12, 17, (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) , including both missense and proteintruncating variants (Fig. 1A) .
The mammalian TRIO gene encodes a 330-kDa protein; as depicted in Figure 1A , tissue-specific alternative splicing generates multiple isoforms (33) (34) (35) (36) (37) (38) . Full length TRIO has three catalytic domains: two guanine nucleotide exchange factor (GEF) domains and a predicted serine/threonine kinase domain. TRIO GEF1 activates both Rac1 and RhoG while GEF2 activates RhoA (33, 39, 40) . TRIO also has accessory domains for protein-protein and protein-lipid interactions, including a Sec14 domain, spectrin repeats, two Src-homology 3 domains (SH3), and an immunoglobulin-like (Ig) domain (34, (41) (42) (43) (44) . Of particular interest, studies in diverse model organisms, including Caenorhabditis elegans, Drosophila melanogaster and mice, as well as human patients, have described important roles for the TRIO family GEF domains in the regulation of dendrite, dendritic spine, and synapse development and function (29, (45) (46) (47) . KALIRIN, a vertebrate paralog of TRIO, is also implicated in human neurological disease and is known from studies in rodents to regulate dendrite and dendritic spine stability (14, (48) (49) (50) (51) (52) (53) (54) . Overall, because of the association of TRIO with neurological disease and its known role in dendrite development (29) , analyzing the impact of variants on TRIO function will improve our understanding of neurodevelopmental disorders that are characterized by dendrite and dendritic spine abnormalities, such as bipolar disorder (8) , schizophrenia (8, 9) , autism (10) and intellectual disability (11) .
This study aims to identify and enumerate TRIO de novo mutations associated with neurodevelopmental disorders, characterize TRIO protein expression in the brain, and analyze the impact of de novo mutations and rare sequence variants on TRIO protein function. We discovered that TRIO contains more protein-coding mutations than expected by random chance, revealed that the TRIO9 isoform is expressed in both human and rodent brain, and showed that TRIO9 levels decrease during development. Furthermore, we prioritized neurodevelopmental disease-associated GEF1 and GEF2 mutations/variants, shown in Figure 1A , based on their potential to impact activity and tested them alongside control variants in GTPase activity assays. While none of the control variants had a major impact on activity, several mutants contained stop codons immediately before the TRIO GEF1 or GEF2 domain and 3 of the remaining 12 mutations/variants showed major changes in GEF activity. Importantly, these three TRIO GEF changes are expected to decrease neurite outgrowth, perhaps consistent with their association with neurodevelopmental disorders. (62, 63) were crossed with NEX-Cre mice under the Neurod6 promoter (64) . WT includes tissue from NEX-Creþ/À and Trioþ/ þ mice; Het is NEX-Creþ/À Trioþ/fl; KO is NEX-Creþ/À Trio fl/fl. NS* indicates a non-specific band (for this to be a genuine TRIO isoform of $165 kDa, it would be detectable with the SR5/6 antibody).
Results
TRIO contains more de novo protein-coding mutations than expected by random chance
De novo mutation and exome sequencing analyses have revealed an abundance of protein-coding mutations and variants associated with neurodevelopmental disorders, including schizophrenia (12, 17, (19) (20) (21) 55, 56) , autism (22) (23) (24) (25) (57) (58) (59) , intellectual disability (26, 27, 29) , bipolar disorder (56) and epileptic encephalopathy (28) . The TRIO gene (ENSG00000038382) is particularly interesting, as exome sequencing analyses on control populations have classified TRIO as 'highly constrained', containing significantly fewer rare missense (60) variants and one sixth the number of protein-truncating variants (61) than expected for a transcript of its size. These data suggest a sensitivity or intolerance of TRIO to mutational changes, making observed mutations highly likely to contribute to disease. To evaluate neurological case-associated genetic variation, de novo mutations are particularly revealing, as these genetic alterations occur for the first time in the affected individual and are not inherited from either unaffected parent. To analyze proteincoding de novo mutations in the TRIO protein, a targeted search of de novo mutation studies was performed for schizophrenia (12, 17, (19) (20) (21) 55) , autism (23) (24) (25) (57) (58) (59) , intellectual disability (26, 27) and epileptic encephalopathy (28) . Along with published studies, this targeted search also included de novo mutations in TRIO from an unpublished exome-sequenced cohort from Taiwan, consisting of 1695 individuals diagnosed with schizophrenia and their unaffected parents (D. Howrigan and B. Neale, personal communication).
From this collection of exomes from neurodevelopmental disorder triads (affected child; unaffected parents), we observed 7 missense, 1 frameshift and 2 nonsense de novo mutations across 7208 independent triads ( Fig. 1A (56) . We tested a subset of TRIO variants from this study that were not observed in controls in the Exome Aggregation Consortium (ExAc) database (http://exac. broadinstitute.org/) and were algorithmically and structurally predicted to be damaging. Of particular interest, the TRIO GEF domains contained the highest density of neurological caseassociated de novo mutations and several rare sequence variants in the whole TRIO gene (Fig. 1A) . Using PolyPhen2, Provean and other prediction algorithms, a large number of these mutations and variants were predicted to damage TRIO function (Table 3 ). To study the actual impact on protein function, we developed and tested TRIO constructs containing the most potentially damaging mutations and variants, as identified by the specific amino acid change, amino acid location and predicted impact. The truncation mutants (R1276stop; K1918stop) were treated as equivalent to the addition of no exogenous GEF. Some non-case-associated variants (I1329F, I1329S, in an additional lane of human cortical extract; molecular weights of standards (kDa) are indicated (67) . (B) qPCR averaged across 8 assays of human fetal and adult brain cDNA; primer locations are indicated (see Fig. 1A and Table 2 ). In each assay, GAPDH was also assayed for every sample, and data are expressed relative to GAPDH; bars show mean 6 SEM. D2113N) were tested as controls for our assays and the mutagenesis process. To complement the PolyPhen2 and Provean predictions, we used Clustal and structure-based analyses to prioritize variants by the structural considerations that could impact function; for example, we tested R2141W and V2220G instead of R2141Q or V2220L. Furthermore, some variants identified in affected individuals were not tested, because they were at sites that tolerate several residues by Clustal analysis across multiple species or were in aqueous loops away from known protein-protein interfaces (L1439M, S1459G, R2086C, K2119E). To evaluate the effects of these mutations and variants, we first needed to identify the major TRIO isoforms expressed in the human brain and the developmental time course over which TRIO is expressed.
Characterization of TRIO isoform expression in human and rodent brain
To investigate TRIO protein expression in rodent and human brain tissues, we generated rabbit antibodies for the Sec14, spectrin repeat 5/6 (SR5/6), GEF2 and putative kinase domains of human TRIO (Fig. 1B ). Antibodies were validated using cortical Quantitative polymerase chain reaction primers were designed to have calculated melt temperatures of 60-62 C and a product length of 120-130 bp (67); data are normalized to the GAPDH signal for each sample and averaged across assays (67) .
extracts from mice harboring a conditional TRIO knockout (62, 63) crossed with NEX-Cre mice under the Neurod6 promoter (64); Neurod6 expression is limited to excitatory neurons in the cerebral cortex (64) . The SR5/6, Sec14 and GEF2 antisera all detected the same overlapping pair of bands (268 and 289 kDa) in rodent cortex, corresponding in size to TRIO9S and TRIO9L, respectively (34) (Fig. 1A) . These bands are decreased in intensity in the heterozygote and largely ablated in the homozygote TRIO knockout mouse (Fig. 1B) . Consistent with this conclusion, the TRIO kinase antibody, which detects recombinant TRIO (not shown), failed to detect a protein of this mass or any other large product in rodent cortical samples (Fig. 1B) ; this result corresponds to previous findings with an independent kinase domain antibody (34) . We next used these antisera to identify the TRIO isoforms present in adult human cortex and hippocampus, brain regions with the highest levels of TRIO (Brainspan; Allen Brain Atlas) (Fig. 2A) ; the samples analyzed were commercially prepared and included a mixture of adult male and female tissue. A major band the size of TRIO9 was detected by the same three antisera but not by kinase domain antibodies, while full-sized recombinant TRIO (analyzed in a parallel lane) was detected by all of the antibodies.
To assess developmental regulation of TRIO expression in humans, cDNAs were prepared from commercial samples: two samples were from adult tissue and two were from fetal samples. Amplicons spanning full-length TRIO were examined (Fig. 1) . Normalized to the GAPDH internal standard, each amplicon in the fetal sample was present at significantly higher levels relative to adult, with a consistent 6.6 6 1 ratio of fetal to adult signal across 20 primer sets spanning the TRIO protein.
Ten of these quantitative polymerase chain reaction (qPCR) primer sets, presented in Figure 2B , revealed comparable amounts of Sec14 domain, GEF1 (DH1) domain, TRIO8 COOH-terminus and GEF2 domain transcripts. Consistent with the immunoblot data, the qPCR analysis revealed virtually no signal for the Exon 48-49 and SH3-2 regions, which would connect GEF2 to the kinase domain, as in Tilgner et al. (65) . Based on both western blot analysis and qPCR, TRIO9 is the major isoform expressed in human cortex and hippocampus.
TRIO isoform levels during development and subcellular localization
To better understand developmental changes in TRIO levels, we prepared extracts from mouse cortex from birth to 6 months of age. Analyzing equal amounts of protein from each age, we found that TRIO9 levels gradually decreased with age (Fig. 3A) ; as a positive control, recombinant TRIO was always detected on the same gel (þTRIO). Expression of postsynaptic density (PSD) protein 95 (PSD95), a marker for the formation of excitatory synapses was also evaluated; as expected, PSD95 levels increased dramatically between postnatal day 7 and postnatal day 31, the time period of maximum synaptogenesis and synaptic pruning (66) . The level of heat shock protein 70 (HSP70) was constant across development.
Since one key to protein function is localization, the subcellular distribution of TRIO proteins was investigated in adult mouse cortex (Fig. 3B ). For comparison, the subcellular localization of the protein made from the 7 kb splice variant of the KALRN gene (Kal7), which is largely localized to the postsynaptic density (67), was evaluated. Equal amounts of protein from each fraction were analyzed. The TRIO antibodies detected proteins the size of TRIO9 (S and/or L) in each fraction. A substantial amount of TRIO was present in the cytosol and the lysed synaptosomes (LS1), indicating that it was soluble. TRIO9 was also recovered from the P3 fraction, which is enriched in endoplasmic reticulum, and in the P2 or synaptosomal membrane fraction. After gradient purification, the PSD-enriched pellet was fractionated into Triton X-100 (TX-100) soluble proteins and purified PSDs. Although TRIO9 was recovered in synaptosomal membranes, with one variant solubilized by TX-100 and the other remaining in the PSDs, TRIO9 was not enriched in the purified PSDs. Kal7, like GluN2B and PSD95, was substantially enriched in purified PSDs [as in Miller et al. (67) ].
Overall, our finding that the TRIO9 isoform predominates in human and rodent brain early in development is consistent with published studies establishing that TRIO levels in several brain regions drop after birth, suggesting it plays a major developmental role (35, 47, 62, (68) (69) (70) . Furthermore, both Rac1 and RhoA, which are activated by the TRIO GEF1 and GEF2 domains, respectively, play central roles in controlling the cytoskeletal rearrangements that power nervous system development (71), highlighting the importance of understanding the impact of mutations and rare variants on the function of these domains for neurodevelopmental disorders.
Disease-associated variants in the TRIO GEF1 domain reduce its activity
To assess the impact of de novo mutations and rare sequence variants in the TGEF1 domain on protein stability and catalytic activity, we established a quantitative cell-based biosensor assay for the activation of Rac1. The Rac1 bioassays use a fluorescence resonance energy transfer-(FRET-)based biosensor in which activation of Rac1 enables intra-sensor interactions with its binding partner PAK. The Rac1 activation-induced conformational change promotes FRET between the cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) within the biosensor, leading to increased emission at 525 nm (72, 73) . The emission spectra for HEK293 cells transfected with the Rac1 biosensor and selected TGEF1 constructs are shown in Figure 4A . Transfection of increasing amounts of wild-type (WT) TGEF1 yielded a dose-dependent increase in Rac1 biosensor FRET, as observed with similar KALIRIN GEF1 constructs (67, 73) .
To quantify the difference in the relative activity of the constructs toward Rac1, cells were transfected with a constant amount of biosensor and increasing amounts of the various TGEF1 expression constructs. Western blot analyses were performed from a portion of the extracts of transfected HEK293 cell lysate (Fig. 4C) , to relate the Rac1 biosensor activity to relative TGEF1 protein levels. The FRET signal at 525 nm obtained for each well was normalized to relative TGEF1 protein levels, as determined by immunoblotting (Fig. 4D) . The dose-dependent response of the R1312W, I1329S, I1329F, D1368V and D1368Y variants were indistinguishable from WT TGEF1 (Fig. 4D) ; the R1312 and D1368 mutations were case-associated variants (Table 1) , while the I1329 mutations were chosen as controls. In contrast, two of the tested disease-associated TGEF1 variants substantially reduced the ability of the protein to activate Rac1: K1431M and F1538Intron (Fig. 4A) . The autism-associated K1431M de novo mutant was only 8% as active as WT TGEF1 when normalized to protein level (n ¼ 8 assays performed in duplicate), likely owing to its position at the TGEF1/Rac1 interface, as identified in the crystal structure (Table 2) . K1431 lies at the interface between TGEF1 and Rac1 (Fig. 4B) , suggesting that the K1431M mutation may reduce binding of TGEF1 to Rac1. The schizophrenia-associated F1538Intron construct (25) , in which the second exon of the pleckstrin-homology (PH) domain is deleted and a 19-residue segment of the intron is translated, showed both the expected smaller protein and very low expression levels, suggesting that this mutant protein was unstable. Furthermore, despite its low level of expression, the activity of the TGEF1 F1538Intron variant was readily detectable and significantly above controls.
Full-length TRIO and TRIO8 are less active than TGEF1, and the K1431M mutation further reduces this activity While the TGEF1 construct provided a useful screening background to test many TRIO sequence variants, testing the impact of the variants on GEF activity within the context of the native protein is essential (Fig. 5) . However, it was not possible to achieve the same level of protein expression with the longer TRIO isoforms as with TRIO8 or TGEF1, owing to toxicity at higher levels of vector (Fig. 5B) . As expected from previous work on KALIRIN (67, 74) and Drosophila Trio (75), the larger TRIO proteins had reduced ability to activate Rac1 compared with TGEF1 alone (Fig. 5A) . While TRIO9 is clearly the major isoform expressed in the human brain, the presence of a second GEF domain could complicate the analysis. To avoid this issue, we opted to evaluate the effect of TGEF1 mutations in TRIO8. When assessed in TRIO8, the K1431M mutation markedly reduced Rac1 activation (Fig. 5C ), as it did in TGEF1 (Fig. 4D) .
The low activity of the autism-and schizophrenia-associated TRIO variants (K1431M, F1538Intron) raised the possibility that a less active GEF could exert a dominant negative effect, interfering with Rac1 activation by a WT allele. To test this possibility, we performed mixing experiments by varying the amounts of vector to match the levels of protein expression (Fig. 5D) . The lesser activities of the K1431M and F1538Intron variants were simply additive to WT TGEF1 activity, with no evidence of competition or a dominant negative effect. These data suggest that these diseaseassociated de novo variants act as hypomorphs.
A bipolar disorder-associated GEF2 variant yields increased activity, confirming a distinct mode of GEF2 regulation
To assess the impact of de novo mutations and rare sequence variants on TGEF2 activity (Fig. 6A) , we established a quantitative cell-based biosensor assay for RhoA. The RhoA bioassay functions like the Rac1 bioassay, except RhoA activation induces a conformational change by binding to the Rho binding domain of PKN1, promoting FRET between CFP and YFP, leading to emission at 525 nm. As expected, transfection of increasing amounts of WT TGEF2 yielded a dose-dependent increase in RhoA biosensor FRET ( Fig. 6B and C) . As observed for a homologous RhoGEF, p63RhoGEF, the PH portion of TGEF2 exerts an inhibitory effect on the activity of the preceding DH domain (76) (77) (78) . Based upon identified mRNAs that encode the Dblhomology (DH) 2 domain of TRIO but lack the PH2 domain, a shorter TRIO GEF2 isoform (TDH2) was developed (Fig. 6A) (65) . RhoA bioassays performed with TDH2 revealed that, as expected, TDH2 was a more active RhoA GEF than TGEF2, which includes the inhibitory PH2 domain (Fig. 6B and C) .
The dose-dependent responses of the control D2113N variant and the case-related R2141W, D2144N and V2220G variants were indistinguishable from WT TGEF2 (Fig. 6C) . When tested using the shorter TDH2 construct, the D2113N, R2141W and D2144N proteins did not differ from WT TDH2 (Fig. 6C) . Strikingly, the bipolar disorder-associated M2145T variant in TGEF2 yielded consistently higher RhoA biosensor activity at all levels tested, compared with similar expression levels of WT TGEF2 ( Fig. 6D and E) . M2145 is located at the boundary of the DH2 and PH2 domains of TRIO, suggesting that the M2145T variant restricts the ability of the TRIO PH2 domain to inhibit the TRIO DH2 domain. The M2145T variant had no effect on TDH2 function ( Fig. 6D and E) , supporting the suggestion that M2145T restricts the ability of the PH2 domain to inhibit the DH2 domain in TGEF2 and supporting the model by which the PH2 domain negatively regulates TDH2 RhoA GEF activity.
Discussion
In this study, we confirmed that TRIO9, but not full length TRIO, is the major postnatal TRIO isoform in both human and mouse brain. TRIO9 is developmentally regulated, decreasing in expression after birth as previously observed (35, 62, 47, (68) (69) (70) . Furthermore, the TRIO gene was shown to have an enrichment of de novo mutations in neurodevelopmental disease in this study and previous studies (13, 31, 32) and a high number of rare sequence variants not observed in control individuals. Prediction algorithms, such as PolyPhen2 and Provean, suggested that many of these mutations and variants were damaging to protein function. We tested these predictions biochemically to identify mechanisms by which they could impact TRIO function, such as reduced expression levels or impaired activity. Owing to the low-throughput nature of these experiments, one limitation was an inability to test every mutation and variant, forcing us to prioritize and only study those that were most likely to impact function based upon algorithmic and structure-based predictions. We discovered that one autismassociated de novo mutation in TGEF1 (K1431M) decreased its activity toward Rac1, likely through impaired TRIO/Rac1 interactions. In contrast, a schizophrenia-associated rare sequence variant (aberrant splicing) in TGEF1 (F1538Intron) was substantially less active, when normalized to protein level, and expressed very poorly, suggesting protein instability. A recent study examined a different mutation that deleted almost all of the PH1 domains in three related patients and, using a Racpulldown activation assay, found that TGEF1 activity was reduced (30) . Since half of the affected individuals in this previous study also have a 15q11.2 microdeletion, it is not clear that the loss of TRIO PH1 was the cause of the intellectual disability and microcephaly (30) . Three additional variants studied exhibit an autosomal dominant inheritance pattern (30) ; however, our mixing experiments strongly suggest that the disease-related TRIO variants lead to haploinsufficiency. We propose that these three variants (30) may also be examples of haploinsufficient alleles, which would exhibit the same inheritance pattern as an autosomal dominant allele.
The situation for TGEF2 is quite different, since the natural splice variant TDH2, which lacks the PH2 domain entirely, is far more active than the larger TGEF2 protein in the RhoA activation assay. Analyzing genetic damage to the TGEF2 domain, one bipolar disorder-associated rare variant (M2145T) impaired TRIO regulation. In particular, M2145T appeared to restrict the ability of the TPH2 domain to negatively regulate the RhoA GEF activity of the TDH2 domain. Overall, this study suggests that neurodevelopmental disease-associated genetic damage may impact the TGEF1 and TGEF2 domains through loss-of-function and gain-of-function mutations/variants, respectively.
Use of algorithms to predict impact of sequence variation on protein function
Of further interest, many of the tested mutations/variants that were predicted to be damaging had no measurable effect on TRIO protein expression or GEF function. Table 3 lists the variants tested in this study and a few selected others. For each, the PolyPhen2 and Provean predictions for damage to the protein structure and function are provided. In general, the predictions identified more mutations/variants as damaging than observed when testing the expression and activity of the isolated GEF domains; the Provean predictions aligned more closely with our data than the PolyPhen2 predictions. In contrast, the Clustal predictions were very instructive; in most cases, if several residues were tolerated at a chosen position, looking across species at similar GEFs, there was a reasonable possibility that the variant would be fully active. If the variation identified by Clustal was only within class (e.g. positively charged K $ R), then a change that was 'out of class' was considered more likely to be deleterious. Similarly, known crystal structures were extremely predictive. For TGEF1, only 1 variant (K1431M; 'out of class') was at a position that could clearly be important, namely the TGEF1/ Rac1 interface, and the change (K ! M) resulted in a similarly large but uncharged residue replacing the positively charged lysine. For TGEF2, the crystal was less predictive, as only a closely related structure was available (not the TGEF2 structure). However, the substitution (M2145T; 'out of class') at the DH2-PH2 boundary would be a logical place for an effect, given the strong inhibition of PH2 on the activity of DH2 (76) (77) (78) .
Model for regulation of neurite outgrowth by TRIO GEF1 and GEF2 domains
Based on these data, we propose a model by which TGEF1 is natively active and signals through Rac1 to promote dendritic initiation and branching; thus loss-of-function mutations in TGEF1 impair proper nervous system development. On the other hand, TGEF2 is natively inhibited, and signals through RhoA to negatively regulate dendritic initiation and branching, such that gain-of-function mutations in TGEF2 impair proper nervous system development. The inclusion of both the GEF1 and GEF2 domains in the same TRIO protein isoform allows for both modules to be physically coupled into an easy 'switch' from dendritic stability to instability when needed. As a next step, the impact of the TRIO K1431M, F1538Intron and M2145T mutations on neurite outgrowth, dendrite arborization and dendritic spine density can be directly assessed by knockdown/rescue experiments in primary neuronal culture. Overall, by understanding this and other molecular pathways underlying neurodevelopmental disorders, treatments targeted at correcting disease mechanisms may be developed in the future.
Materials and Methods
Targeted search for de novo mutation and rare sequence variants in TRIO A targeted search of triad exomes was performed of published and unpublished studies of neurodevelopmental disorders, including epileptic encephalopathy (28) , intellectual disability (26, 27) , autism spectrum disorders (23) (24) (25) (57) (58) (59) 
R1276X
Before GEF1 Schizophrenia a n/a n/a n/a n/a Dead (0 GEF) R1312W GEF1 Autism ( 
K1918X
Before GEF2 Schizophrenia a n/a n/a n/a n/a Dead (0 GEF) R2086C GEF2 Control (56) The subset of variants tested (numbered using NM_007118) with the source of each mutation identified. For each variant, structural predictions using PolyPhen2 
Biosensor assays
The Rac1 biosensor assays using HEK293 cells have been described (73) . The RhoA biosensor developed by van Unen et al. (79) had the same spectral characteristics as the Rac1 biosensor and RhoA assays were also carried out using transiently transfected HEK293 cells. Western blot analyses were performed with rabbit TRIO Sec14 antibody [CT233 (34) ] or with a Myc monoclonal antibody [clone 9E10 (80) ]. Western blots were quantified from non-saturated images using GeneTools from SynGene (67); all wells of HEK293 cells were transfected with a constant amount of Rac1 or RhoA biosensor.
Quantitative polymerase chain reaction
Using fetal and adult human RNA from Clontech and BioChain, random primed cDNA was prepared using the BioRad iScript kit as described (67) . qPCR was performed using the primers listed in Table 2 ; all products were 120-130 bp and all primers had calculated melting temperatures of [60] [61] [62] C. TRIO products were normalized to the GAPDH internal standard, yielding consistent data across eight assays and between commercial sources.
TRIO vector constructs and variants
The vector encoding full-length myc-His-TRIO was described previously and was based on the U42390.1 (short front) sequence (34 The unique COOH-terminal of TDH2 is the extension of Exon 45 into Intron 45 (VMRLLFFKRAPLPSSLSFVLDYFSPHRES*) as identified in 6 transcripts in Tilgner et al. (65) . The full-length TDH2 construct was constructed with a Myc epitope at the NH 2 -terminal by PCR from fetal human RNA from BioChain. The TGEF1-F1538Intron construct, which includes Exon 30, the first of the 2 exons comprising the PH1 domain, then extending into Intron 30, was constructed by PCR to create a COOH-terminal that matched ENST00000509967. Site-directed variants were introduced by mutagenesis with the QuikChange kit (Stratagene); to avoid confusion with the literature, residues are always numbered as for NM_007118 (long front). Subtracting 59 converts NM_007118 amino acid numbers to U42390.1 amino acid numbers, the reference standard used in the Protein Data Bank crystal structures. All constructs were verified by DNA sequencing.
Immunoblotting and Trio fl/fl mice Protein concentrations were determined by BCA Assay (Pierce). Protein amounts loaded are provided in Figure legends . The TRIO Kinase domain antibody was raised by immunization of rabbits (Pocono Rabbit Farm and Laboratory, Canadensis, PA, USA) with the purified products from pMAL-MBP fusion with amino acids 2796-3053 of TRIO (NP_009049) and affinity purified on resin with MBP alone first and then the same bacterial MBP-TRIO protein (81) . TRIO GEF2 (DH2) antibody was raised by immunization of rabbits (Pocono Rabbit Farm and Laboratory) with the purified products from pGEX6P1 fusion with amino acids 1968-2158 of TRIO (NP_009049) and affinity purified on resin with GST first (to remove GST binding) and then the same bacterial GST-TRIO protein (81) . TRIO Sec14 antibody was raised by immunization of rabbits (Covance Research Products, Denver, PA, USA) with the cleaved, purified product from a pGEX6P1 fusion with amino acids 1-234 of TRIO (NP_009049) and affinity purified on resin with the same recombinant protein (82) . The KALIRIN Sec14 (82) , TRIO SR5/6 and TRIO Kinase (C-terminal peptide) (34) antibodies were described previously. The PSD95 (Neuromab 75-028) and HSP70 (Santa Cruz, SC 32239) antibodies are commercial monoclonal mouse antibodies. To test the validity of the new TRIO antisera, conditional TRIO knockout mice (62, 63) were crossed with NEX-Cre mice under the Neurod6 promoter (64), and cortical extracts were subjected to western analysis.
